Home / Health / FDA Greenlights New Myasthenia Gravis Treatment
FDA Greenlights New Myasthenia Gravis Treatment
19 Nov
Summary
- FDA approved a new drug for generalized myasthenia gravis.
- The drug treats adults with specific anti-acetylcholine receptor antibodies.
- Regeneron Pharmaceuticals developed the newly approved medication.
On Thursday, November 16, 2026, the US Food and Drug Administration announced its approval of a new drug developed by Regeneron Pharmaceuticals. This medication is indicated for adults diagnosed with generalized myasthenia gravis.
The treatment is specifically for those individuals who test positive for anti-acetylcholine receptor antibodies. This targeted approach aims to provide effective therapy for a defined patient population within the broader myasthenia gravis community.